Skip to main content
. 2012 Nov 7;4(4):563–589. doi: 10.3390/pharmaceutics4040563

Figure 1.

Figure 1

Effect of combretastatin A-4 phosphate (CA4P) (25 mg/kg) [117], NPI (7.5 mg/kg) [132], and combretastatin A-1 Phosphate (OXi4503) (50 mg/kg) (unpublished data) in 200 mm3 C3H mammary carcinomas as measured by initial area under the curve (IAUC) (90 s) (red) and Ktrans from Toft’s model (blue) 3 h following treatment. Bars show mean of tumour median values ± SE.